The estimated Net Worth of Deirdre Gillespie is at least $620 Тысяча dollars as of 9 May 2011. Deirdre Gillespie owns over 99,166 units of La Jolla Pharmaceutical Co stock worth over $616,813 and over the last 19 years Deirdre sold LJPC stock worth over $3,063.
Deirdre has made over 2 trades of the La Jolla Pharmaceutical Co stock since 2011, according to the Form 4 filled with the SEC. Most recently Deirdre exercised 99,166 units of LJPC stock worth $992 on 9 May 2011.
The largest trade Deirdre's ever made was exercising 99,166 units of La Jolla Pharmaceutical Co stock on 9 May 2011 worth over $992. On average, Deirdre trades about 11,505 units every 2 days since 2006. As of 9 May 2011 Deirdre still owns at least 99,166 units of La Jolla Pharmaceutical Co stock.
You can see the complete history of Deirdre Gillespie stock trades at the bottom of the page.
Deirdre's mailing address filed with the SEC is 6455 NANCY RIDGE DRIVE, , SAN DIEGO, CA, 92121.
Over the last 21 years, insiders at La Jolla Pharmaceutical Co have traded over $13,460,170 worth of La Jolla Pharmaceutical Co stock and bought 11,640,515 units worth $137,250,039 . The most active insiders traders include Advisors Llcperceptive Life..., James N Topper и Woodlands Health Ventures F.... On average, La Jolla Pharmaceutical Co executives and independent directors trade stock every 63 days with the average trade being worth of $1,249,971. The most recent stock trade was executed by Craig A Johnson on 8 July 2022, trading 12,000 units of LJPC stock currently worth $47,160.
La Jolla Pharmaceutical Company is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. In December 2017, GIAPREZA™ (angiotensin II) was approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. In August 2019, GIAPREZA was approved by the European Commission (EC) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. LJPC-0118 (artesunate) is La Jolla's investigational product for the treatment of severe malaria.
La Jolla Pharmaceutical Co executives and other stock owners filed with the SEC include: